CSF2
Granulocyte-macrophage colony-stimulating factor
As of the edition of 20 October 2026, CSF2 (granulocyte-macrophage colony-stimulating factor, UniProt P04141) has 6 drugs tested at it and 13 companies on the list, 9 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04141
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 11
- Disease areas
- Immune system; Bones, joints and muscles; Skin and connective tissue; Cancer; Infections; Digestive system; Lungs and airways; Blood and lymph
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 4 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pexastimogene devacirepvec | Stopped | Phase 3 | none listed |
| Otilimab | Stopped | Phase 3 | none listed |
| Namilumab | Stopped | Phase 2 | none listed |
| Lenzilumab | Stopped | Phase 3 | none listed |
| Plonmarlimab | Active | Phase 3 | none listed |
| Gimsilumab | Went quiet | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Engaged | 4 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| GSK | Route A |
| SillaJen | Route A |
| Gilead Sciences | Route A |
The other 10 companies at CSF2
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at CSF2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.